Galapagos NV (GLPG) Receiving Somewhat Positive Press Coverage, Analysis Shows
News coverage about Galapagos NV (NASDAQ:GLPG) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galapagos NV earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.4353258417711 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Cempra, Inc. (CEMP) has a value of $3.15 per share While Galapagos NV (GLPG) is stand at $101.51 – Stocks Gallery (stocksgallery.com)
- ETFs with exposure to Galapagos NV : September 19, 2017 (finance.yahoo.com)
- Galapagos NV :GLPG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 (finance.yahoo.com)
- Galapagos NV (GLPG) PT Raised to $120 at Stifel on Positive KOL Feedback on GLPG1690 for IPF – StreetInsider.com (streetinsider.com)
- Galapagos NV (GLPG) Price Target Raised to $120.00 (americanbankingnews.com)
A number of brokerages have recently weighed in on GLPG. Royal Bank Of Canada began coverage on Galapagos NV in a report on Thursday, September 14th. They issued a “sector perform” rating and a $98.00 price target for the company. Stifel Nicolaus upped their price objective on Galapagos NV from $101.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, September 15th. BidaskClub upgraded Galapagos NV from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. BTIG Research restated a “buy” rating and set a $98.00 price objective on shares of Galapagos NV in a research note on Tuesday, June 20th. Finally, Nomura upped their price objective on Galapagos NV from $108.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, August 11th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $103.71.
Galapagos NV (NASDAQ GLPG) opened at 101.61 on Thursday. Galapagos NV has a 52 week low of $57.16 and a 52 week high of $103.54.
COPYRIGHT VIOLATION NOTICE: “Galapagos NV (GLPG) Receiving Somewhat Positive Press Coverage, Analysis Shows” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/21/galapagos-nv-glpg-receiving-somewhat-positive-press-coverage-analysis-shows.html.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.